查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
感染疾病臨床檢驗分子診斷的全球市場:策略與趨勢，各用途，各技術，各國預測 - 附執行和顧問指南(2023年～2027年)
市場調查報告書
商品編碼
1309757

感染疾病臨床檢驗分子診斷的全球市場:策略與趨勢，各用途，各技術，各國預測 - 附執行和顧問指南(2023年～2027年)

Clinical Laboratory Molecular Diagnostics for Infectious Disease Markets. Strategies and Trends. Forecasts by Application (Transplant, Respiratory, etc.) by Country. With Market Analysis & Executive Guides. 2023 to 2027
出版日期: | 出版商: Howe Sound Research | 英文 392 Pages | 商品交期: 最快1-2個工作天內

價格

本報告提供全球感染疾病臨床檢驗分子診斷市場相關調查，提供市場概要，以及各用途，各技術，各產品，用戶趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 市場指南

第2章 簡介和市場定義

第3章 感染疾病- 病原體指南

  • 感染疾病的病原體- 透視
  • 冠狀病毒
  • HIV-人類免疫缺乏病毒(AIDS)
  • HBV-B型肝炎
  • HCV-C型肝炎
  • HPV-人類乳突病毒
  • 流感
  • CTGC-披衣菌感染/淋病
  • 結核
  • MRSA-抗藥性金黃色葡萄球菌
  • VRE-萬古霉素抗藥性腸球菌

第4章 產業概要

  • 市場進入組織
    • 學術研究機關
    • 診斷測試開發商
    • 儀器供應商
    • 藥品·試劑廠商
    • 病理供應商
    • 獨立型臨床檢驗室
    • 公共的國立/地區研究所
    • 醫院檢驗室
    • 臨床檢驗室
    • 審核機關
    • 認證機關
  • 臨床檢驗市場區隔
  • 產業結構

第5章 市場趨勢

  • 成長促進因素
  • 阻礙成長的要素
  • 測量，自動化，診斷趨勢

第6章 臨床檢驗的MDx感染疾病的最近趨勢

第7章 主要企業競爭分析

  • Abbott Laboratories
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company
  • bioMérieux Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Cepheid (Danaher)
  • Hologic
  • Ortho Clinical Diagnostics
  • Perkin Elmer
  • Qiagen
  • Roche Molecular Diagnostics
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.

第8章 全球感染疾病臨床檢驗分子診斷市場

  • 各國全球市場概要
  • 各用途的全球市場- 概要

第9章 全球感染疾病臨床檢驗分子診斷市場- 各用途

  • 呼吸系統
  • 血液媒介病毒
  • 移植
  • 院內感染
  • 生殖健康
  • C19 單層
  • 其他

第10章 附錄

OVERVIEW:

The Molecular Diagnostics - Infectious Disease sector of the clinical diagnostics industry is poised for further growth. A market that just keeps on growing but is becoming more complex and segmented. Find out what's happening in this informative report. And find out about the impact of multiplex assays which threaten to change diagnosis and treatment forever.

Infectious disease testing directly benefits from the explosion in biotechnology, especially genomics. Learn all about it in this new report. A range of dynamic trends are pushing market growth and company valuations.

Trends like:

  • Multiplex testing
  • pathogen evolution and pandemics
  • biotechnology advances in genetics
  • climate change
  • globalization
  • the rise of rapid testing

Exciting technical developments especially in the seesaw between nucleic acid testing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication.

All report data is available in Excel format on request.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1 Market Guides

  • 1.1 Situation Analysis
  • 1.2 Market Shares of Leading Companies - Table and Chart

2 Introduction and Market Definition

  • 2.1 Market Definition
    • 2.1.1 Market Size
    • 2.1.2 Currency
    • 2.1.3 Years
  • 2.2 Methodology
    • 2.2.1 Methodology
    • 2.2.2 Sources
    • 2.2.3 Authors
  • 2.3 Perspective: Healthcare and the IVD Industry
    • 2.3.1 Global Healthcare Spending
    • 2.3.2 Spending on Diagnostics
    • 2.3.3 Important Role of Insurance for Diagnostics

3 The Infectious Diseases - Guide to the Pathogens

  • 3.1 Infectious Disease Pathogens - The Big Picture
    • 3.1.1 Viruses
    • 3.1.2 Bacteria
    • 3.1.3 Fungi
    • 3.1.4 Parasites
    • 3.1.5 Prions
    • 3.1.6 Virulence
    • 3.1.7 Transmission
  • 3.2 The Coronavirus
    • 3.2.1 Severe acute respiratory syndrome (SARS)
    • 3.2.2 Middle East respiratory syndrome (MERS)
    • 3.2.3 COVID-19. The SARS CoV 2 Virus.
      • 3.2.3.1 Signs and symptoms
      • 3.2.3.2 Transmission
      • 3.2.3.3 Diagnosis
      • 3.2.3.4 Prevention
      • 3.2.3.5 Management
      • 3.2.3.6 Prognosis
  • 3.4 HIV - Human Immunodeficiency Virus (AIDS)
    • 3.4.1 Virology
      • 3.4.1.1 Classification
      • 3.4.1.2 Structure and genome
      • 3.4.1.3 Tropism
      • 3.4.1.4 Replication cycle
      • 3.4.1.5 Genetic variability
    • 3.4.2 Diagnosis
    • 3.4.3 Testing
      • 3.4.3.1 Antibody tests
      • 3.4.3.2 Point of Care Tests (POCT)
      • 3.4.3.3 Antigen Tests
      • 3.4.3.4 Nucleic acid-based tests (NAT)
      • 3.4.3.5 Other tests used in HIV treatment
  • 3.5 HBV - Hepatitis B
    • 3.5.1 Virology
      • 3.5.1.1 Genome
      • 3.5.1.2 Pathogenesis
      • 3.5.1.3 Hepatitis B virus replication
      • 3.5.1.4 Serotypes and genotypes
    • 3.5.2 Mechanisms
    • 3.5.3 Diagnosis
    • 3.5.4 Market Opportunity Analysis
  • 3.6 HCV - Hepatitis C
    • 3.6.1 Taxonomy
      • 3.6.1.1 Structure
      • 3.6.1.2 Genome
    • 3.6.2 Molecular biology
    • 3.6.3 Replication
    • 3.6.4 Genotypes
      • 3.6.4.1 Clinical importance
    • 3.6.5 Market Opportunity Analysis
  • 3.7 HPV - Human papillomavirus
    • 3.7.1 Virology
      • 3.7.1.1 E6/E7 proteins
      • 3.7.1.2 Role in cancer
      • 3.7.1.3 E2 research
      • 3.7.1.4 Latency period
      • 3.7.1.5 Clearance
    • 3.7.2 Diagnosis
      • 3.7.2.1 Cervical testing
      • 3.7.2.2 Oral testing
      • 3.7.2.3 Testing men
      • 3.7.2.4 Other testing
    • 3.7.3 Market Opportunity Analysis
  • 3.8 Influenza
    • 3.8.1 Virology
      • 3.8.1.1 Types of virus
      • 3.8.1.2 Influenzavirus A
      • 3.8.1.3 Influenzavirus B
      • 3.8.1.4 Influenzavirus C
      • 3.8.1.5 Structure, properties, and subtype nomenclature
      • 3.8.1.6 Replication
    • 3.8.2 Testing
      • 3.8.2.1 Advantages/Disadvantages of Molecular Assays
    • 3.8.3 Market Opportunity Analysis
  • 3.9 CTGC - Chlamydia/Gonorhea
    • 3.9.1 Gonorrhea
      • 3.9.1.1 Diagnosis
      • 3.9.1.2 Screening
    • 3.9.2 Chlamydia
      • 3.9.2.1 Diagnosis
      • 3.9.2.2 Screening
    • 3.9.3 Testing
      • 3.9.3.1 Nucleic acid amplification tests (NAATs).
      • 3.9.3.2 Performance of NAAT Tests
    • 3.9.4 Market Opportunity Analysis
  • 3.10 Tuberculosis
    • 3.10.1 Mycobacteria
    • 3.10.2 Diagnosis
      • 3.10.2.1 Active tuberculosis
      • 3.10.2.2 Latent tuberculosis
    • 3.10.3 Epidemiology
    • 3.10.4 Molecular Diagnostic Tests
    • 3.10.5 Market Opportunity Analysis
  • 3.11 MRSA - Methicillin-resistant Staphylococcus aureus
    • 3.11.1 Diagnosis
    • 3.11.2 FDA Approved Molecular Tests
    • 3.11.3 Market Opportunity Analysis
  • 3.12 VRE - Vancomycin-resistant Enterococcus
    • 3.12.1 FDA Approved MDx Tests for VRE
    • 3.12.2 Market Opportunity Analysis
  • 3.13 VRE - Vancomycin-resistant Enterococcus
    • 3.13.1 FDA Approved MDx Tests for VRE
    • 3.13.2 Market Opportunity Analysis

4 Industry Overview

  • 4.1 Players in a Dynamic Market
    • 4.1.1 Academic Research Lab
    • 4.1.2 Diagnostic Test Developer
    • 4.1.3 Instrumentation Supplier
    • 4.1.4 Chemical/Reagent Supplier
    • 4.1.5 Pathology Supplier
    • 4.1.6 Independent Clinical Laboratory
    • 4.1.7 Public National/regional Laboratory
    • 4.1.8 Hospital Laboratory
    • 4.1.9 Physicians Office Lab (POLS)
    • 4.1.10 Audit Body
    • 4.1.11 Certification Body
  • 4.2 The Clinical Laboratory Market Segments
    • 4.2.1 Traditional Market Segmentation
    • 4.2.2 Laboratory Focus and Segmentation
    • 4.2.3 Segmenting the Syndromic Testing Market
  • 4.3 Industry Structure
    • 4.3.1 Hospital Testing Share
    • 4.3.2 Economies of Scale
    • 4.3.3 Hospital vs. Central Lab
    • 4.3.4 Physician Office Lab's
    • 4.3.5 Physician's and POCT

5 Market Trends

  • 5.1 Factors Driving Growth
    • 5.1.1 New Genotypes Creating New Markets
    • 5.1.2 Aging Population a Boon for All Diagnostics
    • 5.1.3 Developing World Driving ID Dx Growth
    • 5.1.4 Point of Care - Why Centralization is Losing Steam
    • 5.1.5 Self Testing
    • 5.1.6 The Need for Speed
    • 5.1.7 The COVID Pandemic
  • 5.2 Factors Limiting Growth
    • 5.2.1 Lower Costs
    • 5.2.2 Infectious Disease is Declining
    • 5.2.3 Wellness Hurts
    • 5.2.4 Economic Growth improves Living Standards
  • 5.3 Instrumentation, Automation and Diagnostic Trends
    • 5.3.1 Traditional Automation and Centralization
    • 5.3.2 The New Automation, Decentralization and Point Of Care
    • 5.3.3 Instruments Key to Market Share
    • 5.3.4 Bioinformatics Plays a Role
    • 5.3.5 PCR Takes Command
    • 5.3.6 Next Generation Sequencing Fuels a Revolution
    • 5.3.7 NGS Impact on Pricing
    • 5.3.8 Whole Genome Sequencing, A Brave New World
    • 5.3.9 Companion Diagnostics Blurs Diagnosis and Treatment

6 Clinical Laboratory MDx Infectious Disease Recent Developments

  • 6.1 Recent Developments - Importance and How to Use This Section
    • 6.1.1 Importance of These Developments
    • 6.1.2 How to Use This Section
  • 6.2 Spindiag Seeks Investors for Rapid PCR System
  • 6.3 Sorrento Therapeutics Nabs Contract for Dx Platform
  • 6.4 Kephera Planning Menu of Infectious Disease Tests
  • 6.5 Oxford Nanopore and BioMérieux to Develop IDDx
  • 6.6 SD Biosensor Eyes Global Expansion
  • 6.7 Selux Dx Next Gen Phenotyping Gets FDA Clearance
  • 6.8 Takara Developing High-Throughput Multiplex Panels
  • 6.9 BioGX Debuts New Point-of-Care Molecular Testing System
  • 6.10 Nanopath MDx Platform Providing 15-Minute Results
  • 6.11 ProtonDx Commercializing Rapid MDx Instrument
  • 6.12 Siemens Healthineers to Develop Next-Gen, High-Throughput MDx Platform
  • 6.13 Hologic Obtains CE Mark for MDx Epstein-Barr, BK Virus Assays
  • 6.14 Pathogenomix Infectious Disease Platform Uses Cloud-Based Analytics, NGS
  • 6.15 Accelerate Diagnostics Anticipates Growth
  • 6.16 Growth of Decentralized Testing Expected to Continue
  • 6.17 Lumos Diagnostics Expanding Test Portfolio
  • 6.18 Study Validates Karius Cell-Free DNA to Detect Hundreds of Pathogens
  • 6.19 CareDx, IDbyDNA Develop Infectious Disease Dx for Transplant Patients
  • 6.20 Accelerated Development of CRISPR as a Diagnostic Platform
  • 6.21 Lab-on-a-Chip Infection Test Threatens Clinical Laboratory Role

7 Key Companies and Competitive Analysis

  • 7.1 Abbott Laboratories
  • 7.2 Beckman Coulter Diagnostics
  • 7.3 Becton, Dickinson and Company
  • 7.4 bioMérieux Diagnostics
  • 7.5 Bio-Rad Laboratories, Inc.
  • 7.6 Cepheid (Danaher)
  • 7.7 Hologic
  • 7.8 Ortho Clinical Diagnostics
  • 7.9 Perkin Elmer
  • 7.10 Qiagen
  • 7.11 Roche Molecular Diagnostics
  • 7.12 Siemens Healthineers
  • 7.13 Thermo Fisher Scientific Inc.

8 The Global Market for Clinical Laboratory MDx Infectious Disease

  • 8.1 Global Market Overview by Country
    • 8.1.1 Table - Global Market by Country
    • 8.1.2 Chart - Global Market by Country
  • 8.2 Global Market by Application - Overview
    • 8.2.1 Table - Global Market by Application
    • 8.2.2 Chart - Global Market by Application - Base/Final Year Comparison
    • 8.2.3 Chart - Global Market by Application - Base Year
    • 8.2.4 Chart - Global Market by Application - End Year
    • 8.2.5 Chart - Global Market by Application - Share by Year
    • 8.2.6 Chart - Global Market by Application - Segments Growth

9 Global Clinical Laboratory MDx Infectious Disease Markets - By Application

  • 9.1 Respiratory
    • 9.1.1 Table Respiratory - by Country
    • 9.1.2 Chart - Respiratory Growth
  • 9.2 Blood Borne Virus
    • 9.2.1 Table Blood Borne Virus - by Country
    • 9.2.2 Chart - Blood Borne Virus Growth
  • 9.3 Transplant
    • 9.3.1 Table Transplant - by Country
    • 9.3.2 Chart - Transplant Growth
  • 9.4 Hospital Acquired Infections
    • 9.4.1 Table Hospital Acquired Infections - by Country
    • 9.4.2 Chart - Hospital Acquired Infections Growth
  • 9.5 Reproductive Health
    • 9.5.1 Table Reproductive Health - by Country
    • 9.5.2 Chart - Reproductive Health Growth
  • 9.6 C19 Singleplex
    • 9.6.1 Table C19 Singleplex - by Country
    • 9.6.2 Chart - C19 Singleplex Growth
  • 9.7 Other
    • 9.7.1 Table Other - by Country
    • 9.7.2 Chart - Other Growth

10 Appendices

  • 10.1 United States Medicare System: Laboratory Fees Schedule
  • 10.2 The Most Used IVD Assays
  • 10.3 The Highest Grossing Assays

Table of Tables

  • Table 1 Market Share of Leading Companies
  • Table 2 Viral Pathogens and Families
  • Table 3 Characteristics of Coronavirus Pandemic Infections
  • Table 4 COVID-19 Symptoms
  • Table 5 Classification of HIV Species
  • Table 6 HBV Tests - CMS Codes & Prices
  • Table 7 HCV Tests - CMS Codes & Prices
  • Table 8 HPV Clearance Rates
  • Table 9 HPV Tests - CMS Codes & Prices
  • Table 10 HPV Tests, Technology, Types
  • Table 11 Types of Influenza Tests
  • Table 12 Influenza Tests - CMS Codes & Prices
  • Table 13 FDA Cleared Molecular Assays for Influenza
  • Table 14 FDA Cleared NAAT CTGC Tests
  • Table 15 CTGC NAAT Target Sequences and Possible False Reactions
  • Table 16 Influenza Tests - CMS Codes & Prices
  • Table 17 FDA Approved MDx Tests for Tuberculosis
  • Table 18 Tuberculosis Tests - CMS Codes & Prices
  • Table 19 FDA Approved Tests for MRSA
  • Table 20 MRSA Tests - CMS Codes & Prices
  • Table 21 FDA Approved Tests for VRE
  • Table 22 VRE Tests - CMS Codes & Prices
  • Table 23 FDA Approved Tests for VRE
  • Table 24 VRE Tests - CMS Codes & Prices
  • Table 25 Market Players by Type
  • Table 26 Clinical Laboratory Departments and Segments
  • Table 27 Laboratory Management Focus - Different Approaches
  • Table 28 Key Segmentation Variables Going Forward
  • Table 29 Possible Market Segments of Syndromic Multiplex Market
  • Table 30 Five Factors Driving Growth
  • Table 31 Four Factors Limiting Growth
  • Table 32 Seven Key Diagnostic Laboratory Technology Trends
  • Table 33 - Global Market by Region
  • Table 34 Global Market by Application
  • Table 35 Respiratory by Country
  • Table 36 Blood Borne Virus by Country
  • Table 37 Transplant by Country
  • Table 38 Hospital Acquired Infections by Country
  • Table 39 Reproductive Health by Country
  • Table 40 C19 Singleplex by Country
  • Table 41 Other by Country
  • Table 42 Clinical Lab Fee Schedule
  • Table 43 The Most Common Assays
  • Table 44 Largest Revenue Assays

Table of Figures

  • Figure 1 Market Share of Leading Companies Chart
  • Figure 2 Global Health Care Spending
  • Figure 3 The Lab Test Pie
  • Figure 4 Structure of a Typical Virus
  • Figure 5 Mycobacterium Tuberculosis
  • FIGURE 6 STRUCTURE OF CORONAVIRUSES
  • Figure 7 HIV Virion
  • Figure 8 Diagram of the HIV Replication Cycle
  • Figure 9 The Structure of the HBV Virus
  • Figure 10 Hepatitis B Replication
  • Figure 11 Structure of the HCV Virus
  • Figure 12 HCV Replication Cycle
  • Figure 13 Structure of the Influenza Virion
  • Figure 14 Influenza Replication
  • Figure 15 Scanning Electronmicrograph of Tuberculosis
  • Figure 16 The Road to Diagnostics
  • Figure 17 Percentage of World Population Over 65
  • Figure 18 Chart Infectious Disease Decline
  • Figure 19 Centralized vs. Decentralized Laboratory Service
  • Figure 20 A Highly Multiplexed Syndromic Testing Unit
  • Figure 21 The Real Cost to Sequence the Human Genome
  • Figure 22 The Codevelopment Process
  • Figure 23 Global Market Share Chart
  • Figure 24 Global Market by Application - Base vs. Final
  • Figure 25 Global Market by Application Base Year
  • Figure 26 Global Market by Application End Year
  • Figure 27 Application Share by Year
  • Figure 28 Application Segments Growth
  • Figure 29 Respiratory Growth
  • Figure 30 Blood Borne Virus Diagnostics Growth
  • Figure 31 Transplant Growth
  • Figure 32 Hospital Acquired Infections Growth
  • Figure 33 Reproductive Health Growth
  • Figure 34 C19 Singleplex Growth
  • Figure 35 Other Growth